X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, NorthStar will be responsible for the production of 67Cu-SAR-bisPSMA drug product for Clarity’s Phase I/II and Phase III trials being developed in prostate cancer.
Lead Product(s): 67SAR-bisPSMA
Therapeutic Area: Oncology Product Name: 67SAR-bisPSMA
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Recipient: NorthStar Medical Radioisotopes
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 10, 2024
Details:
SAR-bisPSMA (64Cu SAR-bisPSMA/67Cu SAR-bisPSMA) are injectable radiolabelled compounds which are being investogated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.
Lead Product(s): 64Cu-SAR-bisPSMA
Therapeutic Area: Oncology Product Name: SAR-bisPSMA
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
SAR-bisPSMA (64Cu SAR-bisPSMA/67Cu SAR-bisPSMA) are injectable radiolabelled compounds which are being investogated for the treatment of prostate cancer and PSMA-expressing metastatic castrate-resistant prostate cancer.
Lead Product(s): 64Cu-SAR-bisPSMA,67Cu-SAR-bisPSMA
Therapeutic Area: Oncology Product Name: SAR-bisPSMA
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2023
Details:
67Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA is the study drug agent that contains copper-67 & 64 and is used to deliver radiation to tumors that express the PSMA protein. It is being evaluated for the treatment of metastatic castrate-resistant prostate cancer.
Lead Product(s): 64Cu-SAR-bisPSMA,67Cu-SAR-bisPSMA
Therapeutic Area: Oncology Product Name: 64Cu-SAR-bisPSMA
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 29, 2023
Details:
SAR-Bombesin is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).
Lead Product(s): 64Cu-SAR-BBN
Therapeutic Area: Oncology Product Name: SAR-Bombesin
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
SARTATE is highly targeted theranostic radiopharmaceutical. It is developed for diagnosing, staging and subsequently treating cancers that express somatostatin receptor 2. SARTATE product can be used with 64Cu for imaging (64Cu SARTATE) or 67Cu for therapy (67Cu SARTATE).
Lead Product(s): 67Cu-Sartate
Therapeutic Area: Oncology Product Name: 67Cu-Sartate
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: NorthStar Medical Radioisotopes
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
SAR-Bombesin is a Targeted Copper Theranostic that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).
Lead Product(s): 67Cu SAR-bisPSMA,64Cu SAR-bisPSMA
Therapeutic Area: Oncology Product Name: SAR-bisPSMA
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2023
Details:
SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy with broad cancer application. It targets the gastrin-releasing peptide receptor (GRPr).
Lead Product(s): Copper-64 SAR Bombesin,Copper-67 SAR Bombesin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
SAR-Bombesin is a highly targeted pan-cancer radiopharmaceutical with broad cancer application. The product utilises Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator.
Lead Product(s): SAR-bombesin
Therapeutic Area: Oncology Product Name: SAR-BM
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 21, 2022
Details:
SAR-bisPSMA (64Cu-SAR-bisPSMA) reflects a novel approach of connecting two prostate-specific membrane antigen (PSMA) binding motifs to Clarity's proprietary sarcophagene (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator.
Lead Product(s): SAR-bisPSMA
Therapeutic Area: Oncology Product Name: 64Cu-SAR-bisPSMA
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
